De-escalation in low-risk, HER2-positive breast cancer
- PMID: 36858719
- DOI: 10.1016/S1470-2045(23)00064-5
De-escalation in low-risk, HER2-positive breast cancer
Conflict of interest statement
EG declares no competing interests. GC served as consultant or advisor for Roche, Lilly, and Bristol-Myers Squibb; received travel funding from Pfizer and Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche, Pfizer, Lilly, Novartis, and Seagen. FM has received consulting fees or payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Daiichi Sankyo, Novartis, Pfizer, Roche, MSD, SeaGen, Pierre Fabre, and Eli Lilly and support for attending meetings or travel from AstraZeneca, and is supported by FPRC 5xmille Ministero Salute 2017 PTCRC-INTRA 2020, rogetto SEE-HER)and by the Italian Ministry of Health, Ricerca Corrente 2023.
Comment on
-
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.Lancet Oncol. 2023 Mar;24(3):273-285. doi: 10.1016/S1470-2045(23)00051-7. Lancet Oncol. 2023. PMID: 36858723 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
